Kim A. Connelly

FRACP, PhD, MBBS

Scientist

Biography

Dr. Kim Connelly is a Cardiologist and Scientist who is both nationally recognized as an expert in echocardiography, cardiovascular MRI and the impact of diabetes upon cardiac function and ventricular remodeling. His work has been recognized evident by winning the “Young Investigator of the Year Award” by the Canadian Cardiovascular Society, an Early Researcher Award in 2014, and a CIHR New Investigator award in 2014.

Dr. Connelly runs a basic research laboratory at the Keenan Research Centre at St. Michael’s Hospital where he focuses upon basic mechanisms of disease – primarily around the role of pathological extracellular matrix accumulation and the pro-sclerotic cytokine transforming growth factor beta, with a focus upon translating discoveries into therapies in humans. He developed the first hemodynamically validated model of diabetes induced HFpEF. He is the Director of the Krembil Stem Cell Facility at St. Michael’s Hospital and uses regenerative cell based therapies to improve cardiac and renal dysfunction as a result of diabetes. He has research support from the HSF of Canada, CIHR and CFI along with significant research support from the pharmaceutical industry. His work has been published in journals such as the NEJM, Circulation, Journal of the American college of Cardiology, Circulation Research, Diabetes, Cell Metabolism and Lancet Endocrinology and Diabetes.

His H index is 45, and I index of 140.

Dr Connelly is immediate past president of the Canadian Society of Cardiac Magnetic resonance imaging. He runs a translational imaging laboratory and uses hyperpolarized C13 metabolic imaging to understand metabolism in the human heart in real time, as well as CMR to understand the impact of exercise upon cardiac remodeling. He was senior author of the EMPA HEART study along with Dr Verma and Zinman to assess the mechanism by which the SGLT2i empagliflozin provided cardiac protection in patients with type 2 DM. Finally, he was past section lead of 2018 macrovascular complications section for the Diabetes Canada Clinical practice updates and is current chair of the Canadian Cardiovascular Society guidelines.

Recent Publications

  1. Dauz, JD, Yazaki, K, Akazawa, Y, Meister, TA, Kabir, G, Kadowaki, S et al.. Dual inhibition of TGFβ and PDGF improves RV remodeling and function in response to RV pressure or volume-loading. Physiol Rep. 2025;13 (9):e70339. doi: 10.14814/phy2.70339. PubMed PMID:40323168 PubMed Central PMC12051373.
  2. Sedrak, P, Verma, R, Verma, M, Connelly, KA. Evolving Role of Double and Triple Therapy With GLP-1 Receptor Agonists in Obesity and Cardiovascular Disease. Can J Cardiol. 2025; :. doi: 10.1016/j.cjca.2025.03.037. PubMed PMID:40311673 .
  3. Wu, E, Macklin, S, Zhang, Y, Thai, K, Nghiem, L, Di Ciano-Oliveira, C et al.. Induction of proximal tubular proliferation and lengthening in response to sodium glucose linked cotransporter-2 inhibition in experimental rats. J Diabetes Investig. 2025; :. doi: 10.1111/jdi.70043. PubMed PMID:40260754 .
  4. Yerra, VG, Connelly, KA. MOTS-c: Magical Molecule for Diabetic Cardiomyopathy?. Cardiovasc Drugs Ther. 2025;39 (3):473-476. doi: 10.1007/s10557-025-07689-y. PubMed PMID:40172798 .
  5. Akazawa, Y, Vaidyanathan, S, Dewar, MB, Yazaki, K, Dauz, J, Honjo, O et al.. Homeostatic Role of Decorin in Right Ventricular Pressure Overload and Pulmonary Hypertension Induced Remodeling. JACC Basic Transl Sci. 2025;10 (3):323-341. doi: 10.1016/j.jacbts.2024.10.007. PubMed PMID:40139874 PubMed Central PMC12013849.
  6. Pancaldi, E, Adamo, M, Pagnesi, M, Russo, G, Alessandrini, H, Andreas, M et al.. Right heart failure and mortality in patients undergoing transcatheter tricuspid valve interventions. Int J Cardiol. 2025;429 :133137. doi: 10.1016/j.ijcard.2025.133137. PubMed PMID:40068787 .
  7. Hoxha, T, Alanezi, M, Connelly, KA. Editorial Commentary to Unveiling the Fourth Dimension: Strain Analysis With Computed Tomography Scans in Transcatheter Aortic Valve Replacement Innovation. Can J Cardiol. 2025;41 (5):970-972. doi: 10.1016/j.cjca.2025.01.017. PubMed PMID:39884460 .
  8. Connelly, KA, Ge, Y. Quantitative Myocardial Perfusion Imaging: A Case of "More Than Meets the Eye?". JACC Cardiovasc Imaging. 2024;17 (12):1442-1444. doi: 10.1016/j.jcmg.2024.09.009. PubMed PMID:39632043 .
  9. Kosiborod, MN, Cherney, DZI, Desai, AS, Testani, JM, Verma, S, Chinnakondepalli, K et al.. Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure. J Am Coll Cardiol. 2025;85 (10):971-984. doi: 10.1016/j.jacc.2024.11.014. PubMed PMID:39566872 .
  10. Dorian, P, Lewis, NDH, Angaran, P, Connelly, KA. Absolute and Relative Risk of Exercise: When in Doubt, Let Them Play. Can J Cardiol. 2025;41 (3):545-548. doi: 10.1016/j.cjca.2024.10.006. PubMed PMID:39556068 .
Search PubMed

Affiliations & Other Activities

  • Director, Krembil Stem Cell Facility, St. Michael’s Hospital
  • Staff Cardiologist, Division of Cardiology, St. Michael’s Hospital
  • Member, Richard Lewar Center, University of Toronto
  • Cardiologist, Division of Cardiology, Sunnybrook Health Sciences Centre